News
The Single Best Reason to Buy Novavax Stock Now
Buy the rumor and sell the news doesn't always work out so well. Investors who followed the old adage with Novavax (NASDAQ: NVAX) recently learned that lesson the hard way. Shares of the
Here's Why Geron Corporation Fell as Much as 16.6% Today
Shares of clinical stage biopharma Geron Corporation (NASDAQ: GERN) fell nearly 17% Tuesday after management provided a clinical update on its only drug candidate, imetelstat, which is being
ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down
After popping 14% on Friday follow earnings that didn't justify the increase, shares of ImmunoGen (NASDAQ: IMGN) are down 12.6% at 2:49 p.m. EDT on Monday, also for no apparent reason. The biotech
Up 81.6%: Is Dynavax Technologies Corporation Stock Still a Buy?
Dynavax Technologies Corporation (NASDAQ: DVAX) stock jumped a whopping 81.6% in after-hours trading Friday because of a favorable 12-to-1 advisory committee vote for its experimental hepatitis-B
Novavax, Inc.: Buy the Dip?
Novavax's (NASDAQ: NVAX) investors can't seem to catch a break. The clinical-stage vaccine maker has been down on its luck ever since it released disappointing phase 3 trial results last year for its
The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug
Lipitor is one of the most commonly prescribed medicines on the planet, and one of the men behind it, Roger Newton, is currently working on a cheap and effective cholesterol-lowering drug.In this
Why Dynavax Technologies Corporation Stock Is Slumping Today
Dynavax Technologies Corporation's (NASDAQ: DVAX) stock is slumping this morning after the FDA released the briefing documents for the company's experimental hepatitis B vaccine known as Heplisav-B
3 Under-the-Radar Stocks in the Healthcare Sector
While large-cap stocks tend to grab more of the headlines, there's a whole universe of small-cap companies out there to consider as well. But which of those lesser-known companies are most deserving
Quantum Genomics raises EUR 8.2 Million in Europe and the U.S.
Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases,....
Quantum Genomics lève 8,2 M EUR en Europe et aux Etats-Unis
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), société biopharmaceutique dont la mission est de développer de nouvelles thérapies pour des besoins médicaux non satisfaits dans le....
An Exciting New Drug Is in Clinical Trials for Aurinia Pharmaceuticals
Richard Glickman was the CEO of Aspreva Pharmaceuticals, which put out CellCept, a drug that treats patient with lupus who develop kidney disease. Glickman has moved on to Aurinia Pharmaceuticals
An Exciting New Drug Is in Clinical Trials for Aspreva Pharmaceuticals
Richard Glickman was the CEO of Aspreva Pharmaceuticals, which put out CellCept, a drug that treats patient with lupus who develop kidney disease. Glickman has moved on to Aurinia Pharmaceuticals
Why Pacira Pharmaceuticals Shares Are Crashing 15% Today
Pacira Pharmaceuticals (NASDAQ: PCRX) shares are down 15% at 12:00 p.m. EDT today following word that its pain medicine Exparel didn't perform as well as hoped in key phase 3 studies.Pacira
Why Novavax, Inc Is Tanking Today
After providing investors with a number of clinical updates, Novavax (NASDAQ: NVAX), a clinical-stage biotech focused on vaccines, saw its shares decline 24% as of 11:45 a.m. EDT on Tuesday.Here's a
Why Novavax Stock Spiked Today
Shares of the clinical-stage vaccine-maker Novavax (NASDAQ: NVAX) gained as much as 18.2% today on sky-high volume. This noteworthy uptick was sparked by the anticipation surrounding the company's
Why ImmunoGen, Inc. Jumped Higher Today
ImmunoGen (NASDAQ: IMGN) closed up 12% today on no apparent good news. In fact, there was a bit of bad news on Friday after partner Bayer revealed that anetumab ravtansine, which ImmunoGen helped
Why NeuroDerm Ltd Acquired a Higher Price Today
NeuroDerm (NASDAQ: NDRM) is up 15.5% at 12:05 p.m. EDT after announcing that it will be acquired by Japan-based Mitsubishi Tanabe Pharma for $39 per share. The deal puts the value of the biotech at
3 Beaten-Up Biotechs Bouncing Back in 2017 (Hint: One Is a Marijuana Stock)
Not every stock that falls on tough times is worth buying in portfolios, but sometimes, catalysts can spark shareholder-friendly rallies, and in those situations, it can make sense. For example
Should Investors Brace for Bad News From Novavax's Looming Clinical Update?
One press release last week caused shares of clinical-stage biotech Novavax (NASDAQ: NVAX) to soar nearly 25%. The company didn't announce an FDA approval. It didn't even report results from a
3 Been-There-Done-That Biotech CEOs Who Are Doing it Again
You might want to turn back the clock so that you can profit from Puma Biotechnology's (NASDAQ: PBYI) 212% return this year, but unfortunately, you can't. Instead, you'll just have to go out and find
3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?
Biotechnology's top performing stocks this year have already given investors envy-inspiring returns, but there's reason to believe that Calithera Biosciences (NASDAQ: CALA), Aurinia Pharmaceuticals
BOIRON : 2017 half-year activity
BOIRON 2017 HALF-YEAR ACTIVITY
(Unaudited data)
CUMULATIVE ACTIVITY AS OF THE END OF JUNE 2017
in thousands of euros
2016
2017
Variation at current exchange rates
Variation....
BOIRON : Activité du premier semestre 2017
ACTIVITÉ BOIRON PREMIER SEMESTRE 2017
(Données non auditées)
ACTIVITÉ CUMULÉE À FIN JUIN 2017
en milliers d'euros
2016
2017
Var. taux courant 2017/2016
Var. taux constant....
Here's Why Inovio Pharmaceuticals, Inc. Stock Fell Today
Shares of Inovio Pharmaceuticals, Inc. (NASDAQ: INO), a clinical-stage biotech with a focus on cancer and infectious diseases, fell 13.4% during Wednesday's session. An announcement on Tuesday that
Here's Why AVEO Oncology Rose as Much as 15% Today
Shares of biopharma AVEO Oncology (NASDAQ: AVEO) rose up to 15% this morning as the nearly monthlong momentum continued to keep the roller-coaster ride going. While there has been a steady